Test Price
2,800 AED✅ Home Collection Available
GIPC3 Gene (Autosomal Recessive Deafness Type 15) Genetic Test in UAE | 2800 AED | NGS Analysis
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation by a DHA-licensed genetic expert.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) panel analyzes the GIPC3 gene for pathogenic variants causing autosomal recessive deafness type 15 (DFNB15), offering definitive molecular diagnosis for hereditary hearing loss.
| Feature | Our GIPC3 NGS Test | Closest Alternative (Single-Gene Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% analytical sensitivity & specificity; detects SNVs, indels, and copy number variants | ~99% but limited to known mutations; may miss large rearrangements |
| Methodology | Next-Generation Sequencing (Illumina NovaSeq) with AI-driven variant interpretation | Sanger sequencing, manual curation |
| Speed | 3-4 Weeks from sample receipt | 4-6 Weeks |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) notes: “Genetic testing for GIPC3 provides families with a clear molecular diagnosis for hereditary hearing loss, enabling precise genetic counselling and early intervention planning. The results must be interpreted within the context of audiological assessments and family history. I emphasize that a pathogenic variant confirmation does not predict the severity of hearing loss, and a negative result does not exclude all genetic causes. Our team is committed to guiding you through every step, from pre-test counselling to post-test management, ensuring compassionate and evidence-based care.”
Clinical Advisory
Medication Notice: Do not discontinue any prescribed medication without consulting your treating physician. This test does not require fasting or interruption of regular drugs. Inform your genetic counsellor of any anticoagulant therapy prior to blood draw.
Patient Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide a blood, extracted DNA, or FTA card sample; severe haemophilia or uncontrolled bleeding disorders without a physician’s clearance; refusal to participate in pre-test genetic counselling.
- ER Red Flags: If the patient experiences sudden profound hearing loss, acute vertigo with vomiting, or tinnitus associated with neurological symptoms, seek emergency medical attention immediately before scheduling this elective genomic investigation.
- This test is not indicated for acute diagnostic crises; it is an elective genomic investigation.
Patient FAQ & Clinical Guidance
1. How does this genetic test identify the cause of my child's hearing loss?
This GIPC3 NGS test sequences the entire coding region of the GIPC3 gene to detect pathogenic variants, confirming autosomal recessive deafness type 15 with 99.9% accuracy. It also identifies copy number variations that other methods may miss.
2. What sample types are accepted and how is the collection done at home?
We accept fresh whole blood (EDTA tube), extracted DNA (≥1 µg), or a single blood spot on an FTA card. A DHA-licensed phlebotomist will visit your home for a quick, temperature-controlled cold-chain collection between 8 AM and 11 PM daily.
3. Is genetic counselling mandatory before the test, and what does it involve?
Yes, a pre-test genetic counselling session is mandatory. It includes drawing a detailed family pedigree, explaining autosomal recessive inheritance, discussing possible outcomes, and obtaining informed consent. A complimentary post-test telephonic consultation is also provided.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Sovereignty
- All genetic testing is performed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Patient data is encrypted and stored on sovereign servers within the UAE, ensuring full data sovereignty.
- Laboratory certified ISO 9001:2015 (Certificate: INT/EGQ/2509DA/3139) and licensed by DHA (Facility License: 1143).
Clinical & Logistical Metadata
| Test Name | GIPC3 Gene (Autosomal Recessive Deafness Type 15) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina NovaSeq |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 81320-5 |
| DHA Facility License & Laboratory Address | DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians